Journal profile · ONCOLOGY
Cancer Discovery
ISSN 2159-8274 · eISSN 2159-8290 · American Association for Cancer Research Inc. · UNITED STATES · Founded 2011
Cancer Discovery: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 28.99; hybrid open access; median 189 days to acceptance (61 articles, last 24 months); community-reported acceptance: hard; 400 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Discovery is published by American Association for Cancer Research Inc. and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics and CAR-T cell therapy research, together about 25.7% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Discovery publishes high-impact, peer-reviewed articles describing major advances in research and clinical trials. As the premier cancer information resource, the Journal also presents Review Articles, Perspectives and Commentaries, News stories, and Research Watch summaries of important journal articles to its readers to keep them informed about the latest findings in the field. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic and epidemiologic studies
Source: LetPub
Research area (LetPub): ONCOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine9.5%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology9.1%
- CAR-T cell therapy researchMedicine7.2%
- Lung Cancer Treatments and MutationsMedicine6.1%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.3%
- Immunotherapy and Immune ResponsesImmunology and Microbiology4.9%
- Immune Cell Function and InteractionImmunology and Microbiology4.1%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 28.99LetPub ·
- CiteScore 2026-06
- 26.9LetPub ·
- SJR 2026-06
- 7.39LetPub ·
- SNIP 2026-06
- 4.31LetPub ·
- h-index
- 119LetPub ·
- h-index
- 306OpenAlex ·
- i10-index
- 1,865OpenAlex ·
- 2-year mean citedness
- 7.69OpenAlex ·
- Self-citation rate
- 1.7%LetPub ·
- Share of gold OA articles
- 51.29%LetPub ·
Volume
- Articles per year
- 120LetPub ·
Articles by year OpenAlex count · 8,082 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 331 | 74 | 197 |
| 2025 | 400 | 120 | 1,976 |
| 2024 | 486 | 155 | 7,185 |
| 2023 | 507 | 159 | 9,369 |
| 2022 | 532 | 367 | 24,180 |
| 2021 | 553 | 337 | 31,653 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
189 daysMedian, submission to acceptance · P25–P75 122 days – 297 days
- Acceptance to online
- median 5 days (23 articles)
- Submission to online
- median 262 days
- Sample
- 61 articles with submission and acceptance dates (575 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- HardLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- American Association for Cancer Research Inc.
- Country or region
- UNITED STATES
- Language
- English
- Founded
- 2011
- ISSN
- 2159-8274
- Electronic ISSN
- 2159-8290
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Cancer Discovery
What CAS zone is Cancer Discovery in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Discovery is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Discovery?
The latest impact factor listed by LetPub is 28.99; CiteScore 26.9, h-index 306.
How long does peer review take at Cancer Discovery?
Based on the dates recorded on 61 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 189 days (interquartile range 122–297 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Hard”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Discovery?
According to LetPub and DOAJ records, Cancer Discovery is indexed in SCIE and Scopus.
Is Cancer Discovery open access, and what is the APC?
Cancer Discovery is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .